tumor necrosis factor

Nomenclature: tumor necrosis factor

Family: Cytokines and growth factors

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

This target is also described as a ligand entry: tumour necrosis factor membrane formtumour necrosis factor shed form

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 233 6p21.3 TNF tumor necrosis factor
Mouse - 235 17 B1 Tnf tumor necrosis factor
Rat - 235 20p12 Tnf tumor necrosis factor
Previous and Unofficial Names
TNFSF2
DIF
TNF-alpha
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
GeneCards
GenitoUrinary Development Molecular Anatomy Project
InterPro
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Antagonists
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
etanercept Hs Inhibition - - 2-3
[2-3]
Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
certolizumab pegol Hs Inhibition - - 1,7
[1,7]
adalimumab Hs Inhibition - - 4,6,10
[4,6,10]
golimumab Hs Inhibition - - 5,11
[5,11]
infliximab Hs Inhibition - - 9
[9]
Antibody Comments
See Tracey et al. (2009) for a contemporary review of the mechanisms of action of anti-TNFα therapies (antagonists and antibodies) in immune-mediated inflammatory diseases [8].
Clinically-Relevant Mutations and Pathophysiology
Disease:  Malaria, cerebral, susceptibility to
OMIM:  611162
References: 
Mutations not determined

References

Show »

1. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford)41 (10): 1133-7. [PMID:12364632]

2. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. (1998) Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant. Proc.30 (8): 4126-7. [PMID:9865320]

3. Goldenberg MM. (1999) Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther21 (1): 75-87; discussion 1-2. [PMID:10090426]

4. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci9 (5): 765-779. [PMID:24273556]

5. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z et al.. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum.58 (4): 964-75. [PMID:18383539]

6. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis.61 Suppl 2: ii70-3. [PMID:12379628]

7. Song IH, Rudwaleit M. (2013) Certolizumab pegol in axial spondyloarthritis. Expert Rev Clin Immunol9 (12): 1161-72. [PMID:24215406]

8. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117 (2): 244-79. [PMID:18155297]

9. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109 (1): 129-35. [PMID:7797011]

10. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis. Expert Opin Investig Drugs11 (7): 947-53. [PMID:12084005]

11. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ et al.. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol47 (3): 383-96. [PMID:17322150]

How to cite this page

Cytokines and growth factors: tumor necrosis factor. Last modified on 02/05/2014. Accessed on 28/08/2014. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2635.